Biomarkers for diagnosing sepsis in the emergency department: A consensus document by SIBioC-Medicina di Laboratorio and the Academy of Emergency Medicine and Care

Marcello Ciaccio, Rodolfo Sbrojavacca, Stefano Guzzetti, Fiamma Balboni, Andrea Bellone, Giorgio Da Rin, Andrea Bellone, Giuseppe Lippi, Paola Pauri, Daniele Coen, Paola Pauri, Paola Pauri, Paola Pauri, Fabrizio Giostra, Gianfranco Cervellin, Ivo Casagranda, Tommaso Trenti, Paola Pauri, Davide Giavarina, Mario CavazzaMartina Montagnana

Risultato della ricerca: Articlepeer review

3 Citazioni (Scopus)


This article is drafted as a consensus document involving eight members of the Italian Society of Clinical Biochemistry and Laboratory Medicine (SIBioC) and eight members of the Academy of Emergency Medicine and Care (AcEMC), to whom a questionnaire was submitted for obtaining opinions on some recommendations about the use of biomarkers for diagnosing sepsis and managing antibiotic therapy in the emergency department. These recommendations were drafted following the National Guidelines Program (PNLG). According to the cumulative consent, three "A" recommendations (strongly recommended indication) emerged, which include biomarker availability (always available on prescription), clinical use (always interpreted in according to clinical data) and timing of the request based on half-life of the analyte. Recommendations of type "B" (indications carefully considered) included a general agreement about the clinical usefulness of sepsis biomarkers, the combination of procalcitonin (PCT) and C-reactive protein (CRP), the possibility to be free on prescription to the laboratory, the use of cut-offs favoring a high negative predictive value, the use of more analytically sensitive assays and the possibility of using PCT for monitoring antibiotic therapy, with timing of ordering defined according to the metabolism of the analyte. As regards the specific biomarkers, a similar “B” consensus has been reached for measuring both PCT and CRP, and for measuring lactic acid. The measurement of other biomarkers is discouraged except for presepsin, for which there is still substantial uncertainty in favor or against.
Lingua originaleItalian
pagine (da-a)62-73
Numero di pagine12
RivistaBiochimica Clinica
Stato di pubblicazionePublished - 2018

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.1300.1308???
  • ???subjectarea.asjc.3600.3607???
  • ???subjectarea.asjc.2700.2704???

Cita questo